Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Faught, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Faught, E.
NEUROLOGY 2007;69:S3-S9
© 2007 American Academy of Neurology

Monotherapy in adults and elderly persons

Edward Faught, MD

From the Department of Neurology, University of Alabama School of Medicine, Birmingham, Alabama.

Address correspondence and reprint requests to Dr. Edward Faught, Department of Neurology, University of Alabama at Birmingham Epilepsy Center, Civitan International Research Center 312, 1719 6th Avenue South,Birmingham, AL 35294 faught{at}uab.edu

Treatment of epilepsy with a single drug has many advantages. Potential benefits of monotherapy vs polytherapy include fewer adverse events and better tolerability, avoidance of drug-drug interactions, reduced treatment costs, and improved compliance. Initial treatment should always be monotherapy. Avoidance of pharmacokinetic interactions is a major advantage. Some patients who have achieved seizure control with polytherapy may be candidates for conversion to monotherapy because there is no conclusive evidence that polytherapy provides better seizure control in the majority of patients. Recently published treatment guidelines that take into account the efficacy and tolerability profiles of new and old antiepileptic drugs (AEDs) provide recommendations for drug selection in adults. Elderly patients with epilepsy face unique treatment challenges, which include age-related reductions in liver or kidney function that may alter drug pharmacokinetics. Older persons are more sensitive to CNS side effects; some drugs may exacerbate preexisting problems such as tremor, ataxia, and cognitive difficulty. Many common conditions in the elderly are treated with drugs that are subject to interactions with AEDs. Complex dosing schedules and high drug costs are often barriers to proper care. For all these reasons, monotherapy is especially attractive for the elderly.


This supplement was supported by an educational grant from Novartis Pharmaceuticals Corporation.

Disclosure: Dr. Faught has receired honoraria in excess of $10.000 from the sponsor during the course of this study.

Neurology® supplements are not peer-reviewed. Information contained in Neurology® supplements represents the opinions of the authors. These opinions are not endorsed by nor do they reflect the views of the American Academy of Neurology, Editor-in-Chief, or Associate Editors of Neurology®.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by AAN Enterprises, Inc.